Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...
September 30, 2026, 10:01 to October 7, 2026, 10:01 (JST)This week, progress was made in preparing for U.S. regulatory ...
Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...
Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...
Prioritize North America, cell therapy manufacturing and viral vectors; leverage AI, CRISPR, partnerships and scalable production to accelerate commercializationDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) ...
Pharmaceutical Technology on MSN
Scientists claim Nobel Prize for approach behind light-activated gene therapy
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...
The US FDA has approved Ultragenyx Pharmaceutical’s rebisufligene etisparvovec (Fayuvi) for paediatric patients with ...
A gene therapy makes surviving retinal ganglion cells light-sensitive, allowing blind patients to detect objects using stimulating goggles.
At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...
Zacks Investment Research on MSN
Ultragenyx's gene therapy for Sanfilippo syndrome wins EMA validation
Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...
Regulatory support, biotech advances and R&D partnerships drive Japan’s market, led by cell therapies and pre-commercial manufacturing.Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Japan Cell and Gene ...
Six of ten patients in a small trial improved by two or more steps on a severity scale after one treatment, though the data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results